Previous 10 | Next 10 |
Thinly traded micro cap Forty Seven ( FTSV -0.9% ) is down on below-average volume on the heels of the FDA designating lead candidate magrolimab (formerly 5F9) for Fast Track review for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). More news on: For...
Forty Seven Inc. ( FTSV ) was able to receive funding from the Leukemia & Lymphoma Society ((LLS)) to advance a program using 5F9 to treat patients with myelodysplastic syndrome ((MDS)). It makes sense considering that this biotech was able to achieve impressive data for its phase 1b s...
Forty Seven, Inc. (FTSV) Q2 2019 Earnings Conference Call August 13, 2019, 04:30 PM ET Company Participants Michael Horowicz - Stern IR Mark McCamish - CEO Chris Takimoto - Chief Medical Officer Ann Rhoads - CFO Mark Chao - Founder and VP of Clinical Development Craig Gibbs...
Forty Seven (NASDAQ: FTSV ): Q2 GAAP EPS of -$0.74 in-line. More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings -- -- Received FDA Feedback Suggesting Single-Arm Pivotal Trials May Support Registration in MDS and DLBCL -- -- Entered Exclusive Licensing Agreement with Ono Pharmaceutical to Develop and C...
MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 4:30 p...
MENLO PARK, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced additional funding commitments from The Leukemia & Lymphoma Society (LL...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...